Voyager Acquisition【VACH】銘柄情報

Voyager Acquisition Corporation (VACH) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

10.60

( - )

買値

4.31

売値

15.00

出来高

6,279

10.60 日の範囲 10.60

8.40 52 週間の範囲 15.68

時価総額

67.921M

前日終値

10.60

始値

10.60

時刻

9.78

最終取引時間

財務取引量

US$ 66,557

VWAP

10.60

平均取引量 (3 か月)

US$ 18,319

発行済株式数

6,407,685

配当利回り

PER

43.22

1 株当たり利益 (EPS)

0.22

歳入

純利益

6.74M

Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthc... Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. Voyager Acquisition Corp. was incorporated in 2023 and is based in Brooklyn, New York. 詳細を表示

セクター

業界

ウェブサイト

www.voyageracq.com

本社

Brooklyn, United States

設立

2026

Voyager Acquisition Corporation is listed in the sector of the ナスダック市場 with ticker VACH. The last closing price for Voyager Acquisition was US$10.60. Over the last year, Voyager Acquisition shares have traded in a share price range of US$ 8.40 to US$ 15.68.

Voyager Acquisition currently has 6,407,685 shares in issue. The market capitalisation of Voyager Acquisition is US$67.92 million. Voyager Acquisition has a price to earnings ratio (PE ratio) of 43.22.

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies...

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

ZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed...

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel...

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and...

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug...

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units...

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its...

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.5	4.9504950495	10.1	11.2	9	7732	10.26329815	CS
4	-2.15	-16.862745098	12.75	13.4775	8.4	8876	10.6698915	CS
12	-0.45	-4.07239819005	11.05	15.68	8.4	14513	11.70016289	CS
26	0.06	0.569259962049	10.54	15.68	8.4	83116	10.75850758	CS
52	0.21	2.02117420597	10.39	15.68	8.4	53574	10.67599128	CS
156	0.64	6.42570281124	9.96	15.68	8.4	70391	10.35141742	CS
260	0.64	6.42570281124	9.96	15.68	8.4	70391	10.35141742	CS

VACH - Frequently Asked Questions (FAQ)

What is the current Voyager Acquisition Corporation share price?

The current share price of Voyager Acquisition Corporation is US$ 10.60

How many Voyager Acquisition Corporation shares are in issue?

Voyager Acquisition Corporation has 6,407,685 shares in issue

What is the market cap of Voyager Acquisition Corporation?

The market capitalisation of Voyager Acquisition Corporation is USD 67.92M

What is the 1 year trading range for Voyager Acquisition Corporation share price?

Voyager Acquisition Corporation has traded in the range of US$ 8.40 to US$ 15.68 during the past year

What is the PE ratio of Voyager Acquisition Corporation?

The price to earnings ratio of Voyager Acquisition Corporation is 43.22

What is the registered address of Voyager Acquisition Corporation?

The registered address for Voyager Acquisition Corporation is 131 Concord Street, Brooklyn, New York, 11201

What is the Voyager Acquisition Corporation website address?

The website address for Voyager Acquisition Corporation is www.voyageracq.com

ErnieBilco 2月前

Buy the warrants currently about 1% of common cost

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Voyager Acquisition Corporation (VACH)

Voyager Acquisition Corporation (VACH) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Voyager Acquisition Corporation について

VACH 最新ニュース

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VACH - Frequently Asked Questions (FAQ)

VACH 取引

VACH Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Voyager Acquisition Corporation (VACH)

Voyager Acquisition Corporation (VACH) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Voyager Acquisition Corporation について

VACH 最新ニュース

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VACH - Frequently Asked Questions (FAQ)

VACH 取引

VACH Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する